AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab (August 15, 2006). doi:10.1152/ajpendo.00642.2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/1/E117    most recent
00642.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cornish, J.
Right arrow Articles by Reid, I. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cornish, J.
Right arrow Articles by Reid, I. R.
Submitted on December 20, 2005
Accepted on August 7, 2006

PREPTIN, ANOTHER PEPTIDE PRODUCT OF THE PANCREATIC {beta}-CELL, IS OSTEOGENIC IN VITRO AND IN VIVO

Jillian Cornish1*, Karen E Callon1, Usha Bava1, Maureen Watson1, Xin Xu1, Jian-ming Lin1, Vincent A Chan1, Andrew B Grey1, Dorit Naot1, Christina M Buchanan2, Garth JS Cooper3, and Ian R. Reid1

1 Medicine, University of Auckland, Auckland, New Zealand
2 School of Biological Sciences, University of Auckland, Auckland, New Zealand
3 School of Biological Sciences, University of Auckland, Auckland, New Zealand; Medicine, University of Auckland, Auckland, New Zealand

* To whom correspondence should be addressed. E-mail: j.cornish{at}auckland.ac.nz.

Several hormones that regulate nutritional status also impact on bone metabolism. Preptin is a recently isolated 34-amino acid peptide hormone that is co-secreted with insulin and amylin from the pancreatic {beta}-cells. Preptin corresponds to Asp69-Leu102 of proIGF-II. Increased circulating levels of a pro-IGF-II peptide complexed with IGF binding protein 2 have been implicated in the high bone mass phenotype observed in patients with chronic hepatitis C infection. We have assessed preptin's activities on bone. Preptin dose-dependently stimulated the proliferation (cell number and DNA synthesis) of primary fetal rat osteoblasts and osteoblast-like cell lines at periphysiological concentrations (>10-11M). In addition, thymidine incorporation was stimulated in murine neonatal calvarial organ culture, likely reflecting the proliferation of cells from the osteoblast lineage. Preptin did not affect bone resorption in this model. Preptin induced phosphorylation of p42/p44 MAP kinases in osteoblastic cells in a dose-dependent manner (10-8 - 10-10M), and its proliferative effects on primary osteoblasts were blocked by MAP kinase kinase inhibitors. Preptin also reduced osteoblast apoptosis induced by serum deprivation, reducing the number of apoptotic cells by >20%. In vivo administration of preptin increased bone area and mineralizing surface in adult mice. These data demonstrate that preptin, which is co-secreted from the pancreatic {beta}-cell with amylin and insulin, is anabolic to bone, and may contribute to the preservation of bone mass observed in hyperinsulinemic states such as obesity.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.